|1.||Wanders, J: 2 articles (02/2003 - 04/2001)|
|2.||Jayakumar, Jayanthi: 1 article (05/2014)|
|3.||Anishetty, Sharmila: 1 article (05/2014)|
|4.||Lopus, Manu: 1 article (10/2013)|
|5.||Rawat, Diwan S: 1 article (01/2006)|
|6.||Joshi, Mukesh C: 1 article (01/2006)|
|7.||Joshi, Penny: 1 article (01/2006)|
|8.||Atheaya, Himanshu: 1 article (01/2006)|
|9.||Fishkoff, Steven: 1 article (08/2003)|
|10.||Hillman, Shauna: 1 article (08/2003)|
01/01/2000 - "This report describes a phase I study to evaluate the administration of cemadotin to adult cancer patients by a 5-day continuous intravenous (CIV) infusion. "
12/15/1998 - "Cemadotin is in phase II clinical trials as a promising cancer chemotherapeutic agent. "
12/01/1998 - "Cemadotin-HCl (10.0 to 27.5 mg/m2/day every three weeks) was administered as a 24-hour intravenous (i.v.) continuous infusion to patients with advanced cancer. "
10/01/2013 - "Several analogs of DL15, including LU 103793 and tasidotin, have been progressed to clinical trials for different types of cancer. "
05/01/2014 - "Cemadotin is a derivative of natural anti-tumor peptide dolastatin-15; hence these compounds were docked against all three IAPs. "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
08/01/2003 - "A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer."
08/01/2003 - "A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). "
|3.||Breast Neoplasms (Breast Cancer)
02/01/2003 - "Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer."
02/01/2003 - "These results do not support the further evaluation of LU 103793 in metastatic breast cancer patients using this dose and schedule."
02/01/2003 - "The aim of this study was to evaluate the efficacy and tolerability of LU 103793 in patients with metastatic breast cancer who had been previously treated with two lines of chemotherapy for advanced disease. "
|4.||Melanoma (Melanoma, Malignant)
|5.||Hypertension (High Blood Pressure)
|1.||cemadotin (LU 103793)
|6.||soblidotin (TZT 1027)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)